Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...
TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was ...
Rigel, of South San Francisco, California, is positioning R788 (tamatinib fodium), an inhibitor of Syk kinase, as a direct challenger to the tumor necrosis factor-alpha (TNF-α) inhibitor biologics.
55 11 3061 7457 Fax: +55 11 3081 7190 [email protected] Establishing that TNF-α plays an important role in the pathogenesis of several immune-mediated inflammatory diseases led to the development of ...
Isomyosamine targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia. “Findings from the initial observational study will inform our forward move into multiple planned clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results